Special Issue

Applied Invasive Coronary Physiology for Tailored Treatment of Coronary Artery Disease

Message from the Guest Editors

In the past few decades, a great amount of evidence has been collected concerning the role of precise intracoronary invasive physiological evaluation in CADrelated decision making. CAD treatment results regarding safety, efficacy, and cost effectiveness have improved considerably. In line with these developments, current guidelines on coronary interventions emphasize lesion-specific, and in this term, personalized decisions before percutaneous coronary interventions-with the utilization of invasive coronary physiology. However, there are still several open questions in this field, such as identifying the best approach to find appropriate resting and/or hyperemic pressure indices for both the vessel and lesion levels. Similarly, the clinical value of Doppler and thermodilution techniques for the direct assessment of coronary and microvascular flow is also a debated field. At the same time, myocardial microvasculature has come to the forefront of clinical research in order to develop new patient-specific therapeutical options. In the light of the above advances in personalized evaluation as well as the management of CAD, this Special Issue focus on coronary physiology.

Guest Editors

Dr. Gábor Tamás Szabó

Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

Dr. Zsolt Kőszegi

Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

Deadline for manuscript submissions

closed (25 September 2023)

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



mdpi.com/si/111854

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm



Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).